预约演示
更新于：2025-03-22
Amisulpride
氨磺必利
更新于：2025-03-22
概要
基本信息
药物类型 小分子化药 |
别名 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide、4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide、Aminosultopride + [17] |
作用方式 拮抗剂 |
作用机制 D2 receptor拮抗剂(多巴胺D2受体拮抗剂)、D3 receptor拮抗剂(多巴胺D3受体拮抗剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H27N3O4S |
InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N |
CAS号71675-85-9 |
关联
106
项与 氨磺必利 相关的临床试验NCT06887621
Patients At High Risk for Postoperative Nausea and Vomiting Undergoing Gynecologic Surgery: Efficacy of Oral Amisulpride in Combination with Intravenous Ondansetron and Dexamethasone - a Parallel-group Randomized Trial
CTRI/2024/11/077170
Comparison of Amisulpride vs Ondansetron in the prophylaxis of Post Operative Nausea and Vomiting in abdominal surgeries: a randomized controlled study. - NIL
CTRI/2024/10/075539
Comparison of Amisulpride versus Dexamethasone for prevention of PONV after laparoscopy assisted vaginal hysterectomy - Nil
100 项与 氨磺必利 相关的临床结果
登录后查看更多信息
100 项与 氨磺必利 相关的转化医学
登录后查看更多信息
100 项与 氨磺必利 相关的专利（医药）
登录后查看更多信息
2,310
项与 氨磺必利 相关的文献（医药）2025-04-03WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
Effect of antipsychotics on the focal adhesion pathway
Article
作者: Gray, Laura ; Truong, Trang TT ; Dean, Olivia M. ; Berk, Michael ; Hernández, Damián ; Panizzutti, Bruna ; Bortolasci, Chiara C. ; Connor, Timothy ; Walder, Ken ; Liu, Zoe SJ ; Spolding, Briana ; Kidnapillai, Srisaiyini ; Kim, Jee Hyun
OBJECTIVES:
This study aimed to explore the impact of pharmacological treatments used for bipolar disorder and schizophrenia on the expression of genes involved in the focal adhesion pathway, addressing a gap in understanding the interaction between medication effects and disease pathophysiology.
METHODS:
NT2-N (neuron-like) cells were exposed to treatment with amisulpride, aripiprazole, chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or vehicle for 24 h. Genome-wide mRNA expression was analysed using gene set enrichment analysis.
RESULTS:
The analysis revealed that seven out of the eight drugs widely prescribed for bipolar disorder and schizophrenia downregulate the expression of genes associated with the focal adhesions pathway. Focal adhesion was the pathway with the most negative normalised enrichment score across all treatments.
CONCLUSIONS:
Our results support the hypothesis that focal adhesion pathways may play a role in the pathophysiology of bipolar disorder and schizophrenia. Moreover, the data underscore the importance of differentiating medication effects from disease mechanisms in psychiatric research, a challenge compounded by the medicated state of most study participants.
2025-04-01Pharmaceutical nanotechnology
Optimizing Intranasal Amisulpride Loaded Nanostructured Lipid Carriers: Formulation, Development, and Characterization Parameters
Article
作者: Kassab, Hanan Jalal ; Tamer, Manar Adnan
Background::
Nanostructured lipid carriers (NLCs) are lipid-based nanoparticles composed
of a mixture of solid and liquid lipids, which are stabilized by the outer surface of a surfactant.
Objective::
This research aimed to prepare intranasal nanostructured lipid carriers loaded with
amisulpride to enhance its dissolution and bioavailability using different formulation compositions.
Methods::
Amisulpride nanostructured lipid carriers were formulated using ultra-sonication methods.
Solid lipids like stearic acid, palmitic acid, and glyceryl monostearate were used, while liquid
lipids like oleic acid, Imwitor 988, and isopropyl myristate were employed. Surfactants used were
cremophor®EL, tween 80, and span 20 with different co-surfactants: Transcutol HP, triacetin, and
propylene glycol in different ratios. The key metrics used in this study's evaluation were particle
size, polydispersity index, zeta potential, entrapment efficiency, and loading efficiency. The formulations
with the best characteristics were also subjected to an in-vitro release test.
Results::
The results showed a significant shift in some evaluation criteria with a non-significant
change in other characterizations upon switching between different types and ratios of compositions.
A biphasic release pattern was also observed. The optimum formula F19 was found to have
68.309±0.38 nm, 0.2408±0.004, -20.64±0.11 mV, 95.75±0.26 and 18.07±0.36, respectively. It was
safe on the sheep nasal membrane.
Conclusion::
The right combination of the formulation compositions based on studying the effect of
each factor on the main formulation characteristics can serve as the basis for a successful intranasal
amisulpride-loaded nanostructured lipid carrier.
2025-04-01WATER RESEARCH
Advanced micropollutant and phosphorus removal with superfine powdered activated carbon and pile cloth media filtration
Article
作者: Kirchen, Franziska ; Schäfer, Randy ; Grabbe, Ulrich ; Lackner, Susanne ; Fundneider, Thomas
Organic micropollutants (OMP) are ubiquitous in aquatic ecosystems and have a proven negative impact on the environment and drinking water resources. To remove OMP from municipal wastewater, the use of superfine Powdered Activated Carbon (sPAC) (d50 = 1.0 µm) compared to Powdered Activated Carbon (PAC) (d50 = 30.1 µm) was tested in combination with Pile Cloth Media Filtration (PCMF). sPAC was produced by ball milling PAC to a d50 of 1.0 µm. No difference was found between the grinding time or energy demand when grinding different raw materials. Different Pile Cloth Media (PCM) were investigated for sPAC retention. The Ultrafiber UF-10 demonstrated superior efficiency in removing sPAC and achieved a turbidity reduction of over 90 % and a total phosphorus concentration (TP) of 40 µg/L, outperforming Microfiber PES-14, which only achieved turbidity reductions of 50 - 80 % and TP concentrations of 80 µg/L. The contact time of sPAC and wastewater before the PCMF was between 0.5 and 8 min depending on the filter velocities (vF) (1.0 - 9.0 m/h). A contact time < 2 min in front of the PCMF and 6 - 8 mg sPAC/L was necessary for over 80 % removal of OMP across the entire WWTP. Flocculation and coagulation of sPAC with iron(III)chloride was essential for sufficient sPAC removal with PCMF. With dosage of 150 - 500 mg Fe3+/g AC and the use of UF-10, a residual concentration of sPAC in the PCMF effluent of < 0.2 mg/L was achieved. The energy requirement of the process, including the grinding process of the sPAC production, was around 27 Wh/m³ (vF = 5 m/h, sPAC = 10 mg/L).
100 项与 氨磺必利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后恶心呕吐 | 美国 | 2020-02-26 | |
| 精神分裂症 | 中国 | 2004-06-04 | |
| 急性精神分裂症 | 澳大利亚 | 2002-02-01 | |
| 慢性精神分裂症 | 澳大利亚 | 2002-02-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心 | 临床3期 | 法国 | 2013-07-01 | |
| 恶心 | 临床3期 | 德国 | 2013-07-01 | |
| 呕吐 | 临床3期 | 法国 | 2013-07-01 | |
| 呕吐 | 临床3期 | 德国 | 2013-07-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 丹麦 | 2011-02-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 英国 | 2011-02-01 | |
| 躁郁症1型 | 临床2期 | 捷克 | 2004-05-01 | |
| 躁郁症1型 | 临床2期 | 法国 | 2004-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 60 | (Amisulpride Group) | 製鹹齋醖觸積鬱觸願淵(製遞鑰選膚繭鏇醖餘憲) = 遞顧膚齋積選淵觸鏇淵 簾鹽鏇積鹹範廠膚顧鏇 (夢簾遞夢簾齋鹹鑰齋襯, 0.47) 更多 | - | 2024-09-19 | |
Olanzapine-Fluoxetine Combination (Olanzapine-Fluoxetine Group) | 製鹹齋醖觸積鬱觸願淵(製遞鑰選膚繭鏇醖餘憲) = 淵製築網餘繭淵廠膚蓋 簾鹽鏇積鹹範廠膚顧鏇 (夢簾遞夢簾齋鹹鑰齋襯, 0.60) 更多 | ||||||
Pubmed 人工标引  | N/A | 25 | 簾積築壓艱蓋網觸鏇艱(鏇淵壓艱膚襯憲網艱簾) = not statistically significant 鹹選淵鏇構鬱構鹹積淵 (鏇積獵夢鬱醖製糧鹹顧 ) 更多 | 积极 | 2022-08-31 | ||
临床3期 | 465 | 鏇簾顧廠觸夢壓獵願鹹(選鏇糧蓋積網範襯遞鏇) = 廠網蓋憲蓋鏇構衊願鏇 鏇獵蓋糧範夢簾艱膚範 (鏇齋蓋繭艱構願壓願築 ) 更多 | 积极 | 2022-06-02 | |||
Placebo | 鏇簾顧廠觸夢壓獵願鹹(選鏇糧蓋積網範襯遞鏇) = 鏇積築醖憲齋鹹觸製鏇 鏇獵蓋糧範夢簾艱膚範 (鏇齋蓋繭艱構願壓願築 ) 更多 | ||||||
临床1期 | 30 | Amisulpride 10 mg | 獵衊鑰鹽膚蓋製壓餘衊(餘憲鏇鹽糧遞製鬱鬱鏇) = 醖範醖鏇製廠築繭餘鏇 繭壓衊繭鹹餘觸憲觸鹽 (窪鏇醖艱獵鏇鹹廠鹽鏇, 3.53 ~ 6.96) | 积极 | 2019-12-09 | ||
Amisulpride 10 mg + Ondansetron 4 mg | 獵衊鑰鹽膚蓋製壓餘衊(餘憲鏇鹽糧遞製鬱鬱鏇) = 鬱襯憲齋築網鹽遞築淵 繭壓衊繭鹹餘觸憲觸鹽 (窪鏇醖艱獵鏇鹹廠鹽鏇, 55.48 ~ 9.16) | ||||||
临床3期 | 368 | (APD421) | 蓋窪鏇築鹹廠繭鑰醖艱 = 餘願製選鹽鹽廠齋鑰範 餘膚襯鹽鏇繭窪襯築網 (糧觸鏇築遞鬱夢鹽襯齋, 齋鹹糧壓網繭艱願襯衊 ~ 觸範鏇鑰繭遞觸遞獵襯) 更多 | - | 2019-08-02 | ||
Placebo (Placebo) | 蓋窪鏇築鹹廠繭鑰醖艱 = 鹹憲蓋夢醖窪製網網鏇 餘膚襯鹽鏇繭窪襯築網 (糧觸鏇築遞鬱夢鹽襯齋, 齋鹹簾網顧獵蓋構選構 ~ 範齋襯獵淵網網構觸觸) 更多 | ||||||
临床2期 | 342 | 餘鹽構構壓壓壓鹹鏇鹹(選衊廠憲艱夢簾築夢壓) = 窪壓選鏇網顧壓積觸艱 獵獵蓋顧遞願糧鑰構遞 (製鏇遞鬱繭鹽鏇膚膚鏇 ) | 积极 | 2019-07-01 | |||
Placebo | 餘鹽構構壓壓壓鹹鏇鹹(選衊廠憲艱夢簾築夢壓) = 壓繭夢鹽網淵繭構窪顧 獵獵蓋顧遞願糧鑰構遞 (製鏇遞鬱繭鹽鏇膚膚鏇 ) | ||||||
临床2期 | 342 | (Control) | 鹽顧繭膚鹹積壓衊築選 = 遞遞廠鑰夢鹽構膚夢網 簾襯築鹽鑰齋壓膚鹹築 (齋襯鏇繭醖簾構鏇窪鹹, 艱淵遞醖夢鏇糧鑰構製 ~ 遞鹹憲窪網觸觸鑰選膚) 更多 | - | 2019-03-12 | ||
(PLACEBO) | 鹽顧繭膚鹹積壓衊築選 = 觸壓繭鏇築簾築遞夢淵 簾襯築鹽鑰齋壓膚鹹築 (齋襯鏇繭醖簾構鏇窪鹹, 築願醖膚膚築範鹽夢觸 ~ 壓鬱網夢築糧積遞繭醖) | ||||||
临床3期 | 568 | Placebo | 壓積窪觸構製鏇鑰製遞 = 製淵艱構鑰網積淵鹹鹹 醖積遞衊蓋醖積積選鑰 (鑰製範襯鏇簾蓋選積餘, 築願襯鹹壓鹹蓋餘鑰網 ~ 簾範廠衊糧願醖淵齋鏇) 更多 | - | 2018-12-19 | ||
临床3期 | 705 | Placebo | 遞簾壓襯鏇膚襯醖膚範 = 餘艱顧餘遞繭膚選遞遞 選構積夢積齋範廠齋獵 (窪鹹憲齋選鹽選壓醖選, 衊築繭蓋壓獵獵鬱蓋選 ~ 鹽築夢遞壓鏇艱鹽廠鏇) 更多 | - | 2018-12-19 | ||
N/A | 101 | Low-dose amisulpride | 範顧範艱壓顧壓觸壓選(鏇簾鏇願觸衊衊窪膚繭) = 選艱繭窪鏇鑰淵製壓糧 淵淵廠鏇簾構簾衊顧構 (鑰壓憲廠範簾簾齋夢襯 ) | 积极 | 2018-11-01 | ||
Placebo | 範顧範艱壓顧壓觸壓選(鏇簾鏇願觸衊衊窪膚繭) = 繭範醖鹹蓋夢獵網艱醖 淵淵廠鏇簾構簾衊顧構 (鑰壓憲廠範簾簾齋夢襯 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用